Home/Pipeline/Athebody® DARPins for pHLA-binding T-Cell Engagers

Athebody® DARPins for pHLA-binding T-Cell Engagers

Oncology

Pre-clinicalPlatform Application

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Platform Application

Company

Athebio

About Athebio

Athebio is a privately held biotech company founded in 2019, leveraging its Athebody® DARPin platform to empower drug developers with a versatile, 'plug & play' scaffold for creating superior targeted therapeutics. The company's mission is to explore and unleash the therapeutic potential of repeat proteins, offering partners a technology characterized by high specificity, solubility, stability, and ease of manufacturing. Athebio's business model is centered on strategic partnerships and technology transfer, as evidenced by its collaboration with POINT Biopharma to develop targeted radioligands.

View full company profile

Therapeutic Areas

Oncology Genetic Diseases

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active